1801.HK Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 11:08):

Stats
Dzisiejszy wolumen	7.41M
Średni wolumen	9.31M
Kapitalizacja rynkowa	66.37B
EPS	HKD0 ( 2024-03-25 )
Następna data zysków	( HKD0 ) 2024-06-20
Last Dividend	HKD0 ( N/A )
Next Dividend	HKD0 ( N/A )
P/E	-57.61
ATR14	HKD0.0430 (0.11%)

Wolumen Korelacja

Długi: -0.19 (neutral)

Krótki: 0.18 (neutral)

Signal:(51.595) Neutral

Innovent Biologics Inc Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Innovent Biologics Inc Korelacja - Waluta/Towar

-0.15
( neutral )

0.22
( neutral )

0.00
( neutral )

-0.32
( neutral )

0.03
( neutral )

Innovent Biologics Inc Finanse

Annual	2023
Przychody:	HKD6.21B
Zysk brutto:	HKD5.07B (81.69 %)
EPS:	HKD-0.660

FY	2023
Przychody:	HKD6.21B
Zysk brutto:	HKD5.07B (81.69 %)
EPS:	HKD-0.660

FY	2022
Przychody:	HKD4.56B
Zysk brutto:	HKD3.63B (79.57 %)
EPS:	HKD-1.460

FY	2021
Przychody:	HKD4.27B
Zysk brutto:	HKD3.70B (86.58 %)
EPS:	HKD-2.31

Financial Reports:

No articles found.

Innovent Biologics Inc

Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, and manufacture of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases. Its principal drug candidate is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody for the treatment of cancer, Hodgkin's lymphoma, and esophageal carcinoma. The company also offers Byvasda for the treatment of several malignant tumors; Halpryza for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and Wegener's granulomatosis; Pemazyre for the treatment of adults with locally advanced or metastatic cholangiocarcinoma; Olverembatinib for the treatment of adult patients with tyrosine kinase inhibitor; and Cyramza to treat four different types of cancers. In addition, it engages in the development of IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein for ocular fundus disease; IBI-306, a human monoclonal antibody to treat hypercholesterolemia; IBI-310, a recombinant human anti CTLA-4 monoclonal antibody for liver cancer and renal cell carcinoma. Further the company develops IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy for the treatment of adults with relapsed or refractory multiple myeloma; IBI-376 for the treatment of recurrent or refractory follicular lymphoma; and IBI-112 for the treatment of psoriasis. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. The company has strategic collaborations with NeoCura Bio-Medical Technology Co. Ltd.; Roche Group; Ascentage Pharma Group International; Eli Lilly and Company; Roche Group; and Bolt Biotherapeutics, Inc. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.